Orion Biotech Announces New IPO of $200,000,000

Orion Biotech Opportunities Corp. (the “Company”) has priced its initial public offering (“IPO”) of 20,000,000 shares at $10.00 per share. Beginning May 13, 2021, the units will be listed on The Nasdaq Capital Market LLC (the “Nasdaq”) and will trade under the symbol “ORIAU.” Each unit consists of one Class A ordinary share of Orion Biotech and one-fifth of a redeemable warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at a price of $11.50 per share.

The Class A ordinary shares and warrants are required to be listed on the Nasdaq under the symbols “ORIA” and “ORIAW,” respectively, until the securities that make up the units begin separate trading. Cantor Fitzgerald & Co. is serving as the offering’s sole book-running manager. To cover any over-allotments, the Company has given the underwriter a 45-day option to buy up to 3,000,000 additional units.

Subject to customary closing conditions, the offering is scheduled to close on May 17, 2021. Only a prospectus is being used to make the bid. When available, copies of the prospectus can be purchased from Cantor Fitzgerald & Co. On May 12, 2021, the Securities and Exchange Commission (the “SEC”) declared a registration statement relating to these securities effective.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, and no selling of these securities will take place in any state or jurisdiction where such an offer, solicitation, or sale would be illegal prior to registration or certification under the securities laws of that state or jurisdiction.